{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophageal+Diseases&page=4",
    "query": {
      "condition": "Esophageal Diseases",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 1878,
    "total_pages": 188,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophageal+Diseases&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophageal+Diseases&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T16:33:10.144Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01770353",
      "title": "MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "ER/PR Positive Breast Cancer",
        "Triple Negative Breast Cancer",
        "Metastatic Breast Cancer With Active Brain Metastasis"
      ],
      "interventions": [
        {
          "name": "Ferumoxytol",
          "type": "DRUG"
        },
        {
          "name": "MM-398",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2012-11",
      "completion_date": "2018-10-02",
      "has_results": true,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-10-12T16:33:10.144Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01770353"
    },
    {
      "nct_id": "NCT04189445",
      "title": "Futibatinib in Patients With Specific FGFR Aberrations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumor",
        "Advanced or Metastatic Gastric or Gastroesophageal Cancer",
        "Myeloid or Lymphoid Neoplasms (MLN)"
      ],
      "interventions": [
        {
          "name": "Futibatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2020-08-05",
      "completion_date": "2024-11-11",
      "has_results": true,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-10-12T16:33:10.144Z",
      "location_count": 11,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04189445"
    },
    {
      "nct_id": "NCT00582972",
      "title": "Does Omeprazole Decrease Intestinal Calcium Absorption?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoporosis",
        "Achlorhydria",
        "GERD",
        "Hip Fracture"
      ],
      "interventions": [
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 23,
      "start_date": "2008-01",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-02-15",
      "last_synced_at": "2026-10-12T16:33:10.144Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00582972"
    },
    {
      "nct_id": "NCT01598077",
      "title": "A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma",
        "HER2 + Breast Cancer",
        "HER2 + Gastric Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Esophageal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "LJM716",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2012-07",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-10-12T16:33:10.144Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01598077"
    },
    {
      "nct_id": "NCT01556919",
      "title": "Esophageal Monitoring Device for Assessing Mucosal Impedance",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "GERD",
        "Esophagitis"
      ],
      "interventions": [
        {
          "name": "Standard of care endoscopy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 429,
      "start_date": "2012-03",
      "completion_date": "2021-07-23",
      "has_results": false,
      "last_update_posted_date": "2021-08-03",
      "last_synced_at": "2026-10-12T16:33:10.144Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01556919"
    },
    {
      "nct_id": "NCT00002951",
      "title": "Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "surgical procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 53,
      "start_date": "1996-06",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2013-09-05",
      "last_synced_at": "2026-10-12T16:33:10.144Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Evanston, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002951"
    },
    {
      "nct_id": "NCT00041808",
      "title": "Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastases, Neoplasm",
        "Colorectal Neoplasms",
        "Esophageal Neoplasms",
        "Stomach Neoplasms",
        "Pancreatic Neoplasms",
        "Breast Neoplasms",
        "Melanoma",
        "Sarcoma",
        "Gastrointestinal Neoplasms",
        "Lung Neoplasms",
        "Liver Neoplasms",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "MTC-DOX for Injection",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "FeRx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2001-07",
      "completion_date": "2003-04",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-12T16:33:10.144Z",
      "location_count": 3,
      "location_summary": "San Diego, California • San Francisco, California • Temple, Texas",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00041808"
    },
    {
      "nct_id": "NCT05708950",
      "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Melanoma",
        "Carcinoma",
        "Sarcoma",
        "Lung Cancer",
        "Prostate Cancer",
        "Breast Cancer",
        "Colo-rectal Cancer",
        "Uterine Cancer",
        "Pancreatic Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Thyroid Cancer",
        "Ovarian Cancer",
        "Kidney Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "KVA12123 - Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "KVA12123 Plus Pembrolizumab - Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "KVA12123 - Dose Expansion",
          "type": "DRUG"
        },
        {
          "name": "KVA12123 Plus Pembrolizumab - Dose Expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kineta Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-03-03",
      "completion_date": "2025-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-12T16:33:10.144Z",
      "location_count": 7,
      "location_summary": "Santa Monica, California • Denver, Colorado • Sarasota, Florida + 4 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05708950"
    },
    {
      "nct_id": "NCT04672434",
      "title": "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Sym021",
          "type": "DRUG"
        },
        {
          "name": "Sym024",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Symphogen A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-11-19",
      "completion_date": "2024-11-22",
      "has_results": false,
      "last_update_posted_date": "2024-12-09",
      "last_synced_at": "2026-10-12T16:33:10.144Z",
      "location_count": 3,
      "location_summary": "Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04672434"
    },
    {
      "nct_id": "NCT01306799",
      "title": "To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Barrett's Esophagus",
        "Erosive Esophagitis",
        "Gastroesophageal Reflux Disease(GERD)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 106,
      "start_date": "2010-01",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2017-03-30",
      "last_synced_at": "2026-10-12T16:33:10.144Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01306799"
    }
  ]
}